🇺🇸 FDA
Pipeline program

JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN

61186372NSC2002

Phase 2 small_molecule active

Quick answer

JNJ-73841937, PEMETREXED , JNJ-61186372, CARBOPLATIN for Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer. is a Phase 2 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials